Hypomethylating Agents Hmas | List of Frontiers open access articles

Case Report

Published on 19 Dec 2024

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

in Hematologic Malignancies

Yunshuo Xiao
Kun Yang
Qiuying Huang
Changqing Wei
Manlv Wei
Zhili Geng
Hui Wu
Tianhong Zhou
Xialoin Yin
Yali Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1477697

2,587 views
2 citations

Systematic Review

Published on 15 Feb 2022

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

in Hematology

Smith Kungwankiattichai
Ben Ponvilawan
Claudie Roy
Pattaraporn Tunsing
Florian Kuchenbauer
Weerapat Owattanapanich

Frontiers in Medicine

doi 10.3389/fmed.2022.801632

9,007 views
29 citations

Review

Published on 25 Feb 2021

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

in Hematologic Malignancies

Kah Keng Wong
Rosline Hassan
Nik Soriani Yaacob

Frontiers in Oncology

doi 10.3389/fonc.2021.624742

13,252 views
42 citations

Mini Review

Published on 22 Sep 2023

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

in Cancer Immunity and Immunotherapy

Johanna Rausch
Evelyn Ullrich
Michael W.M. Kühn

Frontiers in Immunology

doi 10.3389/fimmu.2023.1269012

8,156 views
5 citations

Case Report

Published on 27 Oct 2025

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review

in Hematologic Malignancies

Ruihua Mi
Shuli Guo
Weidong Yang
Lin Wang
Yixuan Ma
Lin Chen
Dongbei Li
Xudong Wei

Frontiers in Oncology

doi 10.3389/fonc.2025.1693061

1,193 views

Mini Review

Published on 09 Mar 2021

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter

in Hematologic Malignancies

Chryssoula Kordella
Eleftheria Lamprianidou
Ioannis Kotsianidis

Frontiers in Oncology

doi 10.3389/fonc.2021.650473

15,184 views
33 citations

Brief Research Report

Published on 15 May 2024

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells

in Cancer Immunity and Immunotherapy

Giulia Corradi
Dorian Forte
Gianluca Cristiano
Andrea Polimeno
Marilena Ciciarello
Valentina Salvestrini
Lorenza Bandini
Valentina Robustelli
Emanuela Ottaviani
Michele Cavo

Frontiers in Immunology

doi 10.3389/fimmu.2024.1386517

4,389 views
8 citations

Original Research

Published on 12 Apr 2021

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

in T Cell Biology

Hussein A. Abbas
Patrick K. Reville
Xianli Jiang
Hui Yang
Alexandre Reuben
Jin Seon Im
Latasha Little
Jefferson C. Sinson
Ken Chen
Andrew Futreal

Frontiers in Immunology

doi 10.3389/fimmu.2021.659625

6,487 views
14 citations

Case Report

Published on 01 Apr 2021

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD

in Cancer Immunity and Immunotherapy

Sun Yao
Chen Jianlin
Qiao Zhuoqing
Li Yuhang
Hu Jiangwei
Hu Guoliang
Ning Hongmei
Zhang Bin
Hu Liangding

Frontiers in Immunology

doi 10.3389/fimmu.2021.639217

6,913 views
13 citations

Original Research

Published on 08 Aug 2022

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

in Cancer Immunity and Immunotherapy

Suxia Geng
Ruohao Xu
Xin Huang
Minming Li
Chengxin Deng
Peilong Lai
Yulian Wang
Ping Wu
Xiaomei Chen
Jianyu Weng

Frontiers in Immunology

doi 10.3389/fimmu.2022.950134

3,804 views
8 citations

Review

Published on 06 Jan 2022

BMT for Myelodysplastic Syndrome: When and Where and How

in Hematologic Malignancies

Akriti G. Jain
Hany Elmariah

Frontiers in Oncology

doi 10.3389/fonc.2021.771614

14,960 views
15 citations

Brief Research Report

Published on 11 Nov 2021

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

in Drugs Outcomes Research and Policies

Lucia Gozzo
Calogero Vetro
Serena Brancati
Laura Longo
Daniela Cristina Vitale
Giovanni Luca Romano
Elisa Mauro
Paolo Fabio Fiumara
Cinzia Maugeri
Marina Silvia Parisi

Frontiers in Pharmacology

doi 10.3389/fphar.2021.748766

6,565 views
22 citations

Original Research

Published on 08 May 2023

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

in Hematologic Malignancies

Audrey Delmas
Laurie Batchelder
Ira Arora
Solene Bayet
David Bruhn
Alice Eberhardt
Stephanie Philpott
Ana Maria Rodriguez-Leboeuf

Frontiers in Oncology

doi 10.3389/fonc.2023.1160966

4,480 views
4 citations

Original Research

Published on 27 Mar 2023

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia

in Hematologic Malignancies

Mariarita Sciumè
Alessandro Bosi
Marta Canzi
Giusy Ceparano
Fabio Serpenti
Pasquale De Roberto
Sonia Fabris
Elena Tagliaferri
Francesca Cavallaro
Francesco Onida

Frontiers in Oncology

doi 10.3389/fonc.2023.1149298

4,715 views
15 citations

Original Research

Published on 15 Sep 2025

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

in Hematology

Jiaying Cheng
Haipeng Fu
Ling Jiang
Yun Huang
Yujiao Zhang
Zhiquan Long
Xuejie Jiang

Frontiers in Medicine

doi 10.3389/fmed.2025.1638176

2,660 views
1 citation

Original Research

Published on 12 Apr 2024

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

in Hematologic Malignancies

Francesco Angotzi
Federica Lessi
Matteo Leoncin
Carla Filì
Mauro Endri
Albana Lico
Andrea Visentin
Stefano Pravato
Anna Candoni
Livio Trentin

Frontiers in Oncology

doi 10.3389/fonc.2024.1370405

4,821 views
9 citations

Articles

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

BMT for Myelodysplastic Syndrome: When and Where and How

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience